Medical researchers at University of Calgary reviewing glioblastoma scans alongside niacin supplements for a clinical trial illustration.
AI에 의해 생성된 이미지

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

AI에 의해 보고됨

A study has identified how an existing medication could improve immunotherapy outcomes for fibrolamellar carcinoma. The rare liver cancer currently has no cure and often spreads before detection. Researchers demonstrated the approach using patient tumor samples.

A Phase II randomized trial found that a six-week, home-based walking and resistance program improved attention test performance and reduced reports that others noticed cognitive problems among patients receiving chemotherapy. Low-dose ibuprofen improved some attention measures but showed mixed results on memory outcomes. The study was published in Cancer.

AI에 의해 보고됨

지난 20년간 홍콩 여성의 폐암 신규 발병 사례가 20% 증가했습니다. 전문가들은 흡연 외에도 유전적 요인과 조리 시 발생하는 연기가 주요 원인이라고 지적합니다.

홍콩의 암 발병 건수는 1983년 이후 두 배 이상 증가했으나, 연령 표준화 사망률은 2023년 인구 10만 명당 71.1명으로 절반 가까이 감소했다.

AI에 의해 보고됨

New research from Fox Chase Cancer Center shows that melanoma spreads more aggressively in middle-aged mice than in young or very old ones. The pattern appears linked to changes in a specific type of immune cell over time.

 

 

 

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부